Received Oct 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 72742 | — |
pregnant patient received Arexvy instead of Abrysvo; received Arexvy instead of Abrysvo; received Arexvy instead of Abrysvo; This non-serious prospective pregnancy case was reported by a nurse via call center representative and described the occurrence of vaccine exposure during pregnancy in a adult female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number 72742, expiry date 12-DEC-2026) for prophylaxis. Co-suspect products included RSV vaccine prot. subunit PreF 2v (Abrysvo) for prophylaxis. On 21-OCT-2025, the patient received Arexvy. The patient did not receive Abrysvo. On 21-OCT-2025, an unknown time after receiving Arexvy, the patient experienced wrong vaccine administered (Verbatim: received Arexvy instead of Abrysvo) and product use in unapproved population (Verbatim: received Arexvy instead of Abrysvo). On an unknown date, the patient experienced vaccine exposure during pregnancy (Verbatim: pregnant patient received Arexvy instead of Abrysvo). The outcome of the vaccine exposure during pregnancy, wrong vaccine administered and product use in unapproved population were not applicable. Pregnancy exposure: Pregnancy Exposure (Arexvy): To mother in third trimester Pregnancy Exposure (Abrysvo): To mother in third trimester Estimated Delivery/Due date: 28-NOV-2025 Pregnancy Outcome: Pregnancy was ongoing Additional Information: GSK Receipt Date: 22-OCT-2025 The nurse had reported that a pregnant patient had received Arexvy instead of Abrysvo. This was 1 of the 6 cases, reported by the same reporter; Sender's Comments: US-GSK-US2025137784:SAME REPORTER US-GSK-US2025137805:SAME REPORTER US-GSK-US2025137800:SAME REPORTER US-GSK-US2025137791:SAME REPORTER US-GSK-US2025137807:SAME REPORTER